Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
4.680
-0.320 (-6.40%)
At close: Nov 3, 2025, 4:00 PM EST
4.680
0.00 (0.00%)
After-hours: Nov 3, 2025, 4:10 PM EST
Serina Therapeutics Employees
As of December 31, 2024, Serina Therapeutics had 13 total employees, including 12 full-time and 1 part-time employees. The number of employees increased by 2 or 18.18% compared to the previous year.
Employees
13
Change (1Y)
2
Growth (1Y)
18.18%
Revenue / Employee
$10,000
Profits / Employee
-$977,538
Market Cap
48.68M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | 2 | 18.18% |
| Dec 31, 2023 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SER News
- 11 hours ago - Serina Therapeutics Provides Regulatory Update on SER-252 Program - GlobeNewsWire
- 26 days ago - Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors - GlobeNewsWire
- 4 weeks ago - Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease - GlobeNewsWire
- 7 weeks ago - Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease - GlobeNewsWire
- 2 months ago - Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway - GlobeNewsWire
- 3 months ago - Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 3 months ago - Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD) - GlobeNewsWire